Huizinga, T W J; Conaghan, Philip G; Martin-Mola, Emilio; Schett, Georg; Amital, Howard; Xavier, Ricardo M; Troum, Orrin; Aassi, Maher; Bernasconi, Corrado Angelo; Dougados, Maxime (2014). Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Annals of the rheumatic diseases, 74(1), pp. 35-43. BMJ Publishing Group 10.1136/annrheumdis-2014-205752
Full text not available from this repository. (Request a copy)OBJECTIVE
To assess the efficacy and safety of tocilizumab (TCZ) plus methotrexate/placebo (MTX/PBO) over 2 years and the course of disease activity in patients who discontinued TCZ due to sustained remission.
METHODS
ACT-RAY was a double-blind 3-year trial. Patients with active rheumatoid arthritis despite MTX were randomised to add TCZ to ongoing MTX (add-on strategy) or switch to TCZ plus PBO (switch strategy). Using a treat-to-target approach, open-label conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), other than MTX, were added from week 24 if Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) >3.2. Between weeks 52 and 104, patients in sustained clinical remission (DAS28-ESR <2.6 at two consecutive visits 12 weeks apart) discontinued TCZ and were assessed every 4 weeks for 1 year. If sustained remission was maintained, added csDMARDs, then MTX/PBO, were discontinued.
RESULTS
Of the 556 randomised patients, 76% completed year 2. Of patients entering year 2, 50.4% discontinued TCZ after achieving sustained remission and 5.9% achieved drug-free remission. Most patients who discontinued TCZ (84.0%) had a subsequent flare, but responded well to TCZ reintroduction. Despite many patients temporarily stopping TCZ, radiographic progression was minimal, with differences favouring add-on treatment. Rates of serious adverse events and serious infections per 100 patient-years were 12.2 and 4.4 in add-on and 15.0 and 3.7 in switch patients. In patients with normal baseline values, alanine aminotransferase elevations >3×upper limit of normal were more frequent in add-on (14.3%) versus switch patients (5.4%).
CONCLUSIONS
Treat-to-target strategies could be successfully implemented with TCZ to achieve sustained remission, after which TCZ was stopped. Biologic-free remission was maintained for about 3 months, but most patients eventually flared. TCZ restart led to rapid improvement.
TRIAL REGISTRATION NUMBER
NCT00810199.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Bernasconi, Corrado Angelo |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0003-4967 |
Publisher: |
BMJ Publishing Group |
Language: |
English |
Submitter: |
Valentina Rossetti |
Date Deposited: |
01 Oct 2014 11:22 |
Last Modified: |
05 Dec 2022 14:37 |
Publisher DOI: |
10.1136/annrheumdis-2014-205752 |
PubMed ID: |
25169728 |
Uncontrolled Keywords: |
DMARDs (biologic) Methotrexate Rheumatoid Arthritis |
URI: |
https://boris.unibe.ch/id/eprint/58491 |
Actions (login required)
 |
Edit item |